Principia Biopharma is a late-stage biopharmaceutical company focused on developing therapies for immune-related diseases. Co.'s proprietary Tailored Covalency® platform enables Co. to design and develop reversible covalent and irreversible covalent, small molecule inhibitors with potencies and selectivities. Co.'s clinical pipeline includes rilzabrutinib, PRN473 Topical, and PRN2246/SAR442168. Co.'s main candidate, rilzabrutinib, a wholly owned Bruton Tyrosine Kinase inhibitor, is in a Phase 3 trial for the treatment of pemphigus (pemphigus vulgaris and pemphigus foliaceus), and in a Phase 1/2 trial for the treatment of Immune Thrombocytopenia. We show 10 historical shares outstanding datapoints in our PRNB shares outstanding history coverage, used to compute PRNB market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing PRNB market cap history over the course of time is important for investors
interested in comparing PRNB's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of PRNB versus a peer is one thing; comparing
PRNB market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like PRNB can fluctuate over the course of history.
With this page we aim to empower investors researching PRNB by allowing them to research the PRNB market cap history. |
Free PRNB Email Alerts:
Video: The Importance of Market Cap
